ALizarin complexone (dihydrate)

• Description :

  ALizarin complexone dihydrate is the dehydrate of Alizarin complexone (HY-121075) . Alizarin complexone is a calcium-binding fluorescent dye. Alizarin complexone stains mineralized areas of bone by binding to calcium crystals. Alizarin complexone inhibits the reverse transcriptase activity of RAV-2, HIV-1, and RSV with IC50 values of 3.8 μg/mL, 45 μg/mL, and 100 μg/mL, respectively. Alizarin complexone exhibits antiviral activity against HIV-1 and RSV. Alizarin complexone delays RSV-induced tumor induction in chickens[1][2][3][4].

• CAS Number :

  [455303-00-1]

• UNSPSC :

  12352005

• Hazard Statement :

  H302-H315-H319-H335

• Target :

  Fluorescent Dye; HIV; Reverse Transcriptase; RSV

• Related Pathways :

  Anti-infection; Others

• Applications :

  Metabolism-protein/nucleotide metabolism

• Field of Research :

  Cancer; Infection; Metabolic Disease

• Smiles :

  O=C(CN(CC(C=C1C2=O)=C(C(O)=C1C(C3=C2C=CC=C3)=O)O)CC(O)=O)O.O.O

• Molecular Formula :

  C19H19NO10

• Molecular Weight :

  421.35

• Precautions :

  P261-P264-P270-P271-P280-P302+P352-P304+P340-P330-P362+P364-P405-P501

• References & Citations :

  [1]Higuchi H, et al. Antiretroviral activities of anthraquinones and their inhibitory effects on reverse transcriptase. Antiviral Res. 1991;15 (3) :205-216. |[2]Oshima T, et al. Selective extraction of histidine derivatives by metal affinity with a copper (II) -chelating ligand complex in an aqueous two-phase system. J Chromatogr B Analyt Technol Biomed Life Sci. 2015;990:73-79. |[3]Yu T, et al. Live imaging of osteoclast inhibition by bisphosphonates in a medaka osteoporosis model. Dis Model Mech. 2016 Feb;9 (2) :155-63. |[4]Cui M, et al. New role of calcium-binding fluorescent dye alizarin complexone in detecting permeability from articular cartilage to subchondral bone. FASEB Bioadv. 2024 Oct 7;6 (11) :539-554.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Biochemical Assay Reagents

• Clinical Information :

  No Development Reported